Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
51 hedge funds and large institutions have $3.01M invested in Forte Biosciences in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 12 closing their positions.
4.01% less ownership
Funds ownership: 27.63% → 23.63% (-4%)
12% less funds holding
Funds holding: 58 → 51 (-7)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
56% less capital inflows, than outflows
Capital inflows: $491K | Capital outflows: $1.13M
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
75% less call options, than puts
Call options by funds: $2K | Put options by funds: $8K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$150K |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$81.6K |
| 3 |
BlackRock
New York
|
+$51.7K |
| 4 |
Millennium Management
New York
|
+$36.9K |
| 5 |
Two Sigma Advisers
New York
|
+$34.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
-$375K |
| 2 |
Renaissance Technologies
New York
|
-$206K |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$80K |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$64K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$51K |
FBRX Hedge Fund Activity: Q4 2019 in Review
51 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2019, worth a combined $3.01M — down 31% from $4.38M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of FBRX and 5 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was GSA Capital Partners, adding an estimated $150K. The largest seller was ISZO Capital Management, exiting entirely with an estimated $375K sold.
- 51 institutional investors held Forte Biosciences (FBRX) as of Q4 2019, down from 58 in Q3 2019.
- Funds reported $3.01M of Forte Biosciences stock for Q4 2019, down 31% quarter-over-quarter.
- 5 funds opened new Forte Biosciences positions in Q4 2019 and 12 closed out, a net change of -7 holders.
- The largest Forte Biosciences buyer in Q4 2019 was GSA Capital Partners, an estimated $150K added.
- The largest Forte Biosciences seller in Q4 2019 was ISZO Capital Management, an estimated $375K sold.
Based on aggregated 13F filings for Q4 2019.